Transrectal ultrasound appearance of squamous cell carcinoma involving the prostate

PURPOSE: This report describes the transrectal ultrasound appearance of squamous cell carcinoma of the prostate. CASE REPORTS: One case of squamous cell carcinoma involving the prostate by extension from a primary urethral carcinoma and a second case of radiation-induced primary prostatic squamous cell carcinoma are presented and the ultrasound findings discussed. CONCLUSIONS: In these 2 cases, squamous cell carcinomas involving the prostate exhibited similar transrectal ultrasound appearances. Both lesions demonstrated an irregular, anterior, relatively hyperechoic appearance. Copyright Copyright 1999 S. Karger AG, Basel     

Transrectal ultrasound in stage A1 prostate carcinoma

Transrectal ultrasound of the prostate was employed on 6 patients found to have Stage A1 carcinoma of the prostate after transurethral resection in order to identify those patients with residual tumor. Two patients were found to have residual tumor by transrectal ultrasound; this was confirmed by ultrasonic guided biopsy of the prostate. Of the remaining patients, an additional 2 on whom the ultrasound did not detect the tumor had tumor less than 1 cm in size, and in 1 patient no residual disease was found in the pathologic specimen. We conclude that ultrasound of the prostate offers another dimension in the staging of patients with Stage A1 carcinoma of the prostate.     

Transrectal ultrasound study of prostate

Better detection of prostate cancer has been achieved in this study of a limited number of patients by the combined use of digital rectal examination and transrectal ultrasound examination. With more experience and modern equipment improved detection of prostate cancer can be expected.     

Primary transitional cell carcinoma of prostate

Primary transitional cell carcinoma of the prostate (TCC-P) is a rare tumor for which definitive therapy remains undefined. To establish a basis for therapy, we analyzed 3 new cases and reviewed the literature. The following points were observed: (1) the true diagnosis is often missed at initial pathologic examination; (2) the tumor has a propensity for extensive local invasion; and (3) it commonly presents with obstructive symptoms in relatively young patients. Treatment recommendations based on our review include: maintenance of a high index of suspicion, especially for fifty to sixty-year-old men with prostate tumors or for suspected prostatic adenocarcinoma that is rapidly progressive and/or unresponsive to hormonal therapy; preoperative pelvic irradiation followed by radical cystoprostatourethrectomy is the treatment of choice in low-stage disease, and combined radiation therapy and chemotherapy should be used for disease beyond the prostate.     

Clinical study of transitional cell carcinoma of the prostate associated with bladder transitional cell carcinoma

BACKGROUND: Transitional cell carcinoma of the prostate in patients with bladder cancer appears to influence the prognosis and affects the decision about therapeutic modality. Therefore, it is important to characterize transitional cell carcinoma associated with bladder cancer. METHODS: From April 1980 to December 1998, 81 male patients underwent total cystoprostatectomies for transitional cell carcinoma of the bladder. The 81 cystoprostatectomy specimens were examined to clarify the characteristics of prostatic involvement by transitional cell carcinoma. The extent, origin, mode of spread and risk factor of prostatic involvement as well as the prognosis were investigated. In 13 of 15 patients with prostatic involvement the prostate was examined by sequential step sections. RESULTS: Prostatic involvement was observed in 15 of 81 patients (18.5%). Prostatic urethral involvement, invasion to prostatic duct/acinus, prostatic stromal invasion and extraprostatic extension and/or seminal vesicle involvement were recognized in 12 (80%), 14 (93.3%), six (40%), and five (33.3%) of the 15 patients, respectively. Twelve of the 15 patients (80%) with prostatic involvement had papillary or non-papillary tumors (i.e. carcinoma in situ) both in the prostatic urethra and prostatic duct. In 10 of these 12 patients (88.3%), there was contiguity between prostatic urethral and ductal tumors. Seven of the 23 patients (30.4%) with carcinoma in situ of the bladder showed prostatic involvement, which increased to 50% in the presence of carcinoma in situ of the trigone or bladder neck. CONCLUSIONS: Eighty per cent of the patients with prostatic involvement showed papillary or non-papillary tumors both in the prostatic urethra and prostatic duct. There was a high level of contiguity between both tumors. Patients with carcinoma in situ of the trigone or bladder neck revealed significantly higher incidence of prostatic involvement.     

多极射频消融治疗前列腺癌的可行性研究

目的探讨射频消融（RFA）治疗前列腺癌的原理、方法的可行性、安全性。方法采用经直肠超声（TRUS）引导下经会阴穿刺为12名晚期前列腺癌患者行前列腺癌射频消融。结果所有12名患者顺利安全地实施射频消融,在一例根治性前列腺癌切除的标本上可见消融区肿瘤细胞完全破坏。结论TRUS引导下经会阴穿刺前列腺癌射频消融从原理和技术上可行,可作为治疗前列腺癌的微创减瘤手段。     

超声引导经直肠前列腺穿刺活检术(附192例报告)

目的评价经直肠超声(TRUS)结合彩色多谱勒血流图象(CDI)对前列腺穿刺活检的指导作用.方法依据TRUS结合CDI选择穿刺点,采用个体化方案对192例PSA＞4ng/m1、可疑前列腺癌(PCA)的患者,行经直肠前列腺穿刺活检,对其中12例PSA持续升高者行重复穿刺.结果 (1)PSA4～10ng/m170例,PCa9例(12.9%)、其中7例CDI有异常血流;阴性61例、其中9例CDI有异常血流.(2)PSA11～150ng/m1122例,PCa47例(38.5%)、其中37例CDI有异常血流;阴性75例、其中14例CDI有异常血流.CDI在PCa与穿刺阴性间比较有极显著性差异(P＜0.001),重复穿刺者12例中发现PCA5例.结论依据TRUS结合CDI采用个体化方案的前列腺穿刺活检术,能提高PCa检出率和减少并发症.     

A case of primary transitional cell carcinoma of the prostate

A 58-year-old man was admitted to our hospital with the complaint of pollakisuria and micturitional pain. The urine cytology showed malignant cells suggesting the urothelial cancer, but various examinations could not reveal the malignant lesion. The prostate was also normal by the digital examination, endoscopy, roentgenography, ultrasonography and serum markers, and the transperineal prostate biopsy showed no malignancy. Three years after the first admission the prostate showed slight hardness and the transperineal biopsy suggested adenocarcinoma of the prostate. Hormonal therapy was then started and the prostate showed no remarkable change until about two years later, when rapid progression of the prostatic tumor was recognized. The transperineal biopsy of the prostate revealed the transitional cell carcinoma with negative staining of Alcian-Blue, PAS and PSA (prostate specific antigen). The epithelia of the bladder and posterior urethra were normal. The radical cystoprostatectomy was done and the histological diagnosis was the pure type of primary transitional cell carcinoma of the prostate. The literatures were reviewed and the clinical differentiation between transitional cell carcinoma and adenocarcinoma of the prostate was discussed.     

A case of primary transitional cell carcinoma of the prostate

A 77-year-old man was referred to our hospital with a complaint of dysuria and right ischiodynia. He had had a hemi-thyroidectomy for thyroid cancer and right cervical lymphadenectomy three years and one year, respectively, before this visit. Prostate cancer was strongly suspected by transrectal examination with prostate specific antigen (PSA) elevated to 77.8 ng/ml. Pathological diagnosis of prostate biopsy specimen was transitional cell carcinoma with grade 3 malignancy and negative staining for PSA. Endoscopic examination showed a normal appearance of bladder and prostatic urethral epithelium. Urine cytology showed no malignant cells. However, immunostaining for PSA revealed that the cervical lymph node specimen resected before was moderately differentiated adenocarcinoma of prostate. He had multiple metastases to mediastinal and retroperitoneal lymph nodes and right ischium. Endocrine therapy (goserelin acetate depot, bicalutamide) and systemic chemotherapy (methotrexate, epirubicin, cisplatin) were performed combined with irradiation to right ischium metastasis. Two months later, he showed a complete response in PSA and partial response in lymph node metastases, but died of cancer 13 months later.     

A case of giant transitional cell carcinoma of the prostate

A 69-year-old man presented with a complaint of pollakisuria, dysuria and anal pain. Digital rectal examination, transrectal ultrasonography and tumor marker of the prostate indicated a giant benign prostate hypertrophy (BPH), but urethrocystogram and magnetic resonance imaging (MRI) of the prostate was not typical of BPH. A diagnosis of giant BPH was made by transrectal needle biopsy of the prostate. However, symptoms of dysuria and anal pain became severe and then a catheter was indwelt into his bladder. A biopsy performed, 3 months later revealed transitional cell carcinoma in the specimens, but he suddenly died of pulmonary infarction.     

Transrectal biopsy of the prostate guided by transrectal ultrasound

The use of transrectal ultrasound in combination with the Biopty System provides a high accurate, efficient, and safe method for the diagnosis and staging of prostate cancer. Because both diagnosis and staging may be attained easily using one comprehensive procedure, we recommend ultrasound guidance be used for all initial biopsies of the prostate. When transrectal ultrasound-guided biopsy of a palpable hypoechoic abnormality is negative for cancer, digitally guided biopsy must subsequently be performed. In some cases, palpable abnormality may not be seen on ultrasound. We advocate the use of our biopsy procedure as an integral extension of transrectal ultrasound of the prostate. In an outpatient setting, biopsy may be performed immediately after finding a suspect lesion on ultrasound. In this way, patients are spared time and anxiety, and society is spared medical costs.     

Transrectal ultrasound in local hyperthermia to the benign prostate

Summary A total of 95 patients suffering from prostatic symptoms due to benign hyperplasia (BPH) and scheduled for surgery elected to participate in a clinical trial of local hyperthermia therapy to the prostate. Transrectal ultrasound (TRUS) was performed before and following completion of the treatment. Changes in volume and in the configuration of the gland were observed. Such changes showed no definite correlation with the clinical and urodynamic results obtained at the 1-month follow-up.     

经直肠超声引导前列腺穿刺活检术诊断前列腺癌

目的　总结和评价经直肠超声引导下前列腺穿刺活检术对前列腺癌诊断的准确率。方法　222 例直肠指检阳性或 PSA>4μg/L的患者应用经直肠超声引导下前列腺6点系统穿刺活检以明确诊断。结果　222 例受检者中病理证实前列腺结节性增生41例、前列腺炎24例、前列腺肉瘤3例、前列腺癌 154 例,其中低分化癌 74 例、中分化癌 58 例、高分化癌 22 例。术后血尿15例、发热6例,其中高热1例,经抗生素治疗后体温恢复正常、尿检阴性。结论　经直肠超声引导下前列腺穿刺活检无需麻醉,患者痛苦小、安全性高,是诊断前列腺癌的可靠方法。     

Transrectal ultrasound for monitoring murine orthotopic prostate tumor

BACKGROUND: The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS: A 6 Fr. 20 MHz catheter-based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM-9 cells into the dorsal prostate of 12-week-old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis-diamminedichloroplatinum (CDDP). RESULTS: By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P < 0.001). Similarly, tumor growth suppression induced by CDDP was clearly detected by TRUS with reasonable accuracy. CONCLUSIONS: A high resolution TRUS allows simple and reliable monitoring of in situ tumor growth and growth suppression, making the mouse orthotopic prostate tumor model more efficient.     

经直肠超声引导13点前列腺系统穿刺活检术160例报告

目的　探讨经直肠超声引导 13点前列腺系统穿刺活检术诊断前列腺癌的临床价值。　方法　对 160例直肠指诊阳性和 (或 )PSA >4ng/ml的患者行经直肠超声引导 13点前列腺系统穿刺活检术。即在标准的经直肠超声引导 6点前列腺系统穿刺活检术同时 ,增加前列腺中间部位及前列腺两侧旁正中线远侧的穿刺点数 ,共穿刺活检 13点。将增加的 7点活检部位病理结果与标准的 6点前列腺系统穿刺活检术进行比较。　结果　 160例患者中确诊为前列腺癌者 5 6例 ( 3 5 % )。 5 6例患者如按 6点穿刺方法 ,将有 12例患者漏诊 ,占 2 1%。 160例患者均未出现严重并发症。　结论　经直肠超声引导 13点前列腺系统穿刺活检术可明显提高前列腺癌的临床检出率